Methylation in aml: Clinical applications

Naveen Pemmaraju; Guillermo Garcia-Manero; Farhad Ravandi

doi:10.1007/978-1-4939-1393-0_22

Methylation in aml: Clinical applications

Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi

Leukemia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Epigenetic therapy is a recognized central therapeutic strategy widely used in treatment of myelodysplatic syndrome (MDS). The approved agents, decitabine and azacytidine, are DNA hypomethylating agents that have been shown in randomized phase III trials to have clinical benefit in MDS patients. New research is investigating the use of these drugs in the setting of acute myeloid leukemia (AML) treatment, especially in older patients. Early studies are demonstrating promising results for the use of decitabine and azacytidine in treatment of AML. Other novel epigenetic/hypomethylating agents as well as chemotherapy combinations including hypomethylating agents represent an active area of research in treatment of AML patients.

Original language	English (US)
Title of host publication	Targeted Therapy of Acute Myeloid Leukemi
Publisher	Springer New York
Pages	441-458
Number of pages	18
ISBN (Electronic)	9781493913930
ISBN (Print)	9781493913923
DOIs	https://doi.org/10.1007/978-1-4939-1393-0_22
State	Published - Jan 1 2015

Keywords

AML
Azacytidine
Decitabine
Hypomethylator

ASJC Scopus subject areas

General Medicine
Pharmacology, Toxicology and Pharmaceutics(all)
General Biochemistry, Genetics and Molecular Biology
General Immunology and Microbiology

Access to Document

10.1007/978-1-4939-1393-0_22

Cite this

@inbook{e49da5a65d2e4bd48df196cfef5275bd,

title = "Methylation in aml: Clinical applications",

abstract = "Epigenetic therapy is a recognized central therapeutic strategy widely used in treatment of myelodysplatic syndrome (MDS). The approved agents, decitabine and azacytidine, are DNA hypomethylating agents that have been shown in randomized phase III trials to have clinical benefit in MDS patients. New research is investigating the use of these drugs in the setting of acute myeloid leukemia (AML) treatment, especially in older patients. Early studies are demonstrating promising results for the use of decitabine and azacytidine in treatment of AML. Other novel epigenetic/hypomethylating agents as well as chemotherapy combinations including hypomethylating agents represent an active area of research in treatment of AML patients.",

keywords = "AML, Azacytidine, Decitabine, Hypomethylator",

author = "Naveen Pemmaraju and Guillermo Garcia-Manero and Farhad Ravandi",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-1393-0_22",

language = "English (US)",

isbn = "9781493913923",

pages = "441--458",

booktitle = "Targeted Therapy of Acute Myeloid Leukemi",

publisher = "Springer New York",

}

TY - CHAP

T1 - Methylation in aml

T2 - Clinical applications

AU - Pemmaraju, Naveen

AU - Garcia-Manero, Guillermo

AU - Ravandi, Farhad

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Epigenetic therapy is a recognized central therapeutic strategy widely used in treatment of myelodysplatic syndrome (MDS). The approved agents, decitabine and azacytidine, are DNA hypomethylating agents that have been shown in randomized phase III trials to have clinical benefit in MDS patients. New research is investigating the use of these drugs in the setting of acute myeloid leukemia (AML) treatment, especially in older patients. Early studies are demonstrating promising results for the use of decitabine and azacytidine in treatment of AML. Other novel epigenetic/hypomethylating agents as well as chemotherapy combinations including hypomethylating agents represent an active area of research in treatment of AML patients.

AB - Epigenetic therapy is a recognized central therapeutic strategy widely used in treatment of myelodysplatic syndrome (MDS). The approved agents, decitabine and azacytidine, are DNA hypomethylating agents that have been shown in randomized phase III trials to have clinical benefit in MDS patients. New research is investigating the use of these drugs in the setting of acute myeloid leukemia (AML) treatment, especially in older patients. Early studies are demonstrating promising results for the use of decitabine and azacytidine in treatment of AML. Other novel epigenetic/hypomethylating agents as well as chemotherapy combinations including hypomethylating agents represent an active area of research in treatment of AML patients.

KW - AML

KW - Azacytidine

KW - Decitabine

KW - Hypomethylator

UR - http://www.scopus.com/inward/record.url?scp=84944632773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944632773&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1393-0_22

DO - 10.1007/978-1-4939-1393-0_22

M3 - Chapter

AN - SCOPUS:84944632773

SN - 9781493913923

SP - 441

EP - 458

BT - Targeted Therapy of Acute Myeloid Leukemi

PB - Springer New York

ER -

Methylation in aml: Clinical applications

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this